Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
63 hedge funds and large institutions have $62.8M invested in Cascadian Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 14 closing their positions.
362% more call options, than puts
Call options by funds: $4.04M | Put options by funds: $874K
42% more capital invested
Capital invested by funds: $44.3M → $62.8M (+$18.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 66 → 63 (-3)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
+$6.78M |
| 2 |
First Eagle Investment Management
New York
|
+$1.72M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$1.37M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.16M |
| 5 |
PC
PointState Capital
New York
|
+$877K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$3.56M |
| 2 |
Millennium Management
New York
|
-$3M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$823K |
| 4 |
Morgan Stanley
New York
|
-$448K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$430K |
CASC Hedge Fund Activity: Q3 2013 in Review
63 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q3 2013, worth a combined $62.8M — up 42% from $44.3M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CASC and 12 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 14 added.
The largest buyer was QVT Financial, opening a new position worth an estimated $6.78M. The largest seller was JP Morgan Chase, cutting an estimated $3.56M.
- 63 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q3 2013, down from 66 in Q2 2013.
- Funds reported $62.8M of Cascadian Therapeutics, Inc. stock for Q3 2013, up 42% quarter-over-quarter.
- 12 funds opened new Cascadian Therapeutics, Inc. positions in Q3 2013 and 14 closed out, a net change of -2 holders.
- The largest Cascadian Therapeutics, Inc. buyer in Q3 2013 was QVT Financial, an estimated $6.78M added.
- The largest Cascadian Therapeutics, Inc. seller in Q3 2013 was JP Morgan Chase, an estimated $3.56M sold.
Based on aggregated 13F filings for Q3 2013.